Farther Finance Advisors’s Avalo Therapeutics AVTX Stock Holding History

Farther Finance Advisors’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-75	Closed	-$1.25K	–	5989
2026 Q1	$1.25K	Buy	+75	New	+$1.17K	﹤0.01%	5039

Other funds holding AVTX

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

AWM

Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Farther Finance Advisors's AVTX Position: Q2 2026 in Review

Farther Finance Advisors sold out of Avalo Therapeutics (AVTX) in Q2 2026, closing a stake of 75 shares — an estimated $1.25K sold.

Farther Finance Advisors first reported a position in AVTX in Q1 2026 and held it in 1 quarter. The position peaked at $1.25K in Q1 2026. 3 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Farther Finance Advisors reported no remaining Avalo Therapeutics position as of Q2 2026 after selling out during the quarter.
Farther Finance Advisors sold 75 Avalo Therapeutics shares in Q2 2026, an estimated $1.25K.
Farther Finance Advisors first reported a position in Avalo Therapeutics in Q1 2026 and held it in 1 quarter.
Farther Finance Advisors's Avalo Therapeutics position peaked at $1.25K in Q1 2026.
3 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.